JBC117

Cat. No.:	HY-157891
CAS No.:	1214531-21-1
Molecular Formula:	$C_{28}H_{30}N_2O_3$
Molecular Weight:	442.55
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

JBC117 is a novel anticancer lead compound targeting Pygo2 PHD. JBC117 can effectively antagonize the cell effect of β-catenin-dependent activity and inhibit the migration and invasion of cancer cells. JBC117 can induce apoptosis[1].

In Vitro

JBC117 (20 μM, 24 h) inhibits the growth of colon cancer (HCT116) and lung cancer (A549) with IC_{50} values of 2.6 and 3.3 μM, respectively[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	HCT116, A549
Concentration:	5, 10, 20 μM
Incubation Time:	72 h
Result:	Downregulated the expression level of Wnt downstream target genes, including Axin2, c-myc and cyclin D1.

Cell Invasion Assay[1]

Cell Line:	HCT116, A549
Concentration:	20 μM
Incubation Time:	24 h
Result:	Decreased the ability to migrate and invasion in a dose-dependent manner.

In Vivo

JBC117 (20 mg/kg/ day, subcutaneously injected for 14 days) shows antitumor activity in mouse xenotransplantation models of colon cancer and lung cancer[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mouse xenograft models of colon and lung cancer[1]
Dosage:	20 mg/kg
Administration:	s.c. for 14 days

Result:	Reduced colon and lung tumor growth by 65% and 93%, respectively. Increased apoptosis in the tumor sections.

REFERENCES

[1]. Ali F, et al. Logical design of an anti-cancer agent targeting the plant homeodomain in Pygopus2. Cancer Sci. 2016 Sep;107(9):1321-8.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA